Germer
Armin Germer, Berlin DE
Patent application number | Description | Published |
---|---|---|
20100145911 | Serverless Replication of Databases - The invention relates to a method for carrying out the serverless replication of databases. The inventive method is characterized in that: a copy of the database on at least one peer of the peer-to-peer computer network is modified; a synchronization request due to the modified copy of the database is generated on the at least one peer of the peer-to-peer computer network; the synchronization request is transmitted to all other peers of the peer-to-peer computer network; the synchronization request is received and executed by all the other peers, and; synchronization confirmations are generated after the execution of the synchronization request on each of the other peers and are communicated to all peers or to all peers with the exception of the peer that transmits the synchronization confirmation to the remaining peers. | 06-10-2010 |
Frauke Germer, Berlin DE
Patent application number | Description | Published |
---|---|---|
20140370575 | GENETICALLY ENHANCED CYANOBACTERIA FOR THE PRODUCTION OF A FIRST CHEMICAL COMPOUND HARBOURING ZN2+, CO2+ OR NI2+ -INDUCIBLE PROMOTERS - One embodiment of the invention is directed to a genetically enhanced cyanobacterium for the production of a first chemical compound, comprising at least one first recombinant gene encoding a first biocatalyst for the production of the first chemical compound, wherein the gene is under the transcriptional control of a Co | 12-18-2014 |
Matthias Germer, Langen DE
Patent application number | Description | Published |
---|---|---|
20090175863 | AGENTS TARGETING CD138 AND USES THEREOF - Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells. | 07-09-2009 |
20090232810 | IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF - Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker. | 09-17-2009 |
20110059082 | AGENT FOR TREATING DISEASE - The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg. | 03-10-2011 |
20110059083 | AGENT FOR TREATING DISEASE - The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days. | 03-10-2011 |
20110059084 | AGENT FOR TREATING DISEASE - The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg. | 03-10-2011 |
20130045199 | Antibody Preparations - An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5 | 02-21-2013 |
20150064170 | Antibody Preparations - An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses. | 03-05-2015 |
Ralph Germer, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20100139682 | Method and apparatus for precise deposition of hair care agents - An apparatus and control method provides for automated, computer control to illuminate hair, sense aspects of that hair, calculate enhancements based on the sensed aspects of the hair, and precisely apply compounds on the hair in spatial conformance with the sensed aspects to create those enhancements. Examples of such compounds are hair coloring agents and hair care agents. | 06-10-2010 |
Soren Germer, Essex County, NJ US
Patent application number | Description | Published |
---|---|---|
20090130660 | Single Nucelotide Polymorphism (SNP) - Association of Type 2 diabetes with single nucleotide polymorphisms and haplotypes are disclosed. Also disclosed are diagnostic applications in identifying those who have Type 2 diabetes or are at risk of developing Type 2 diabetes, and discovery of therapeutic agents and methods of treatment. | 05-21-2009 |
Soren Germer, Maplewood, NJ US
Patent application number | Description | Published |
---|---|---|
20110262462 | POLYMORPHISM MARKERS FOR PREDICTING RESPONSE TO INTERLEUKIN-6 RECEPTOR-INHIBITING MONOCLONAL ANTIBODY DRUG TREATMENT - The present invention provides single nucleotide polymorphisms (SNPs) associated with clinical responsiveness of rheumatoid arthritis patients to treatment with an interleukin-6 receptor antibody such as tocilizumab, and methods of using such SNPs for predicting clinical response to treatment with the antibody. | 10-27-2011 |
20120094284 | Prediction of Early Virological Response in HCV Treatment - The present invention is based on the discovery of associations that exist between single nucleotide polymorphisms (SNPs) on chromosome 19 and virological outcomes in a diverse population of patients with hepatitis C virus (HCV) who received interferon-based treatment. | 04-19-2012 |
20120094389 | Single Nucleotide Polymorphisms That Predict HCV Treatment Outcomes - The present invention is based on the discovery of associations that exist between single nucleotide polymorphisms (SNPs) on chromosome 4 and virological outcomes in a diverse population of patients with hepatitis C virus (HCV) who received interferon-based treatment. | 04-19-2012 |